Galapagos N.V. Cash Flow Conversion Efficiency
Galapagos N.V. cash flow conversion efficiency. Based on the latest financial reports, Galapagos N.V. (GLPG) has a cash flow conversion efficiency ratio of -0.024x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-78.61 Million ≈ $-91.91 Million USD) by net assets (€3.25 Billion ≈ $3.80 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Galapagos N.V. (2004–2025)
Cash flow conversion efficiency of Galapagos N.V. from 2004 to 2025. This chart illustrates how Galapagos N.V.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Galapagos N.V. for real-time trading data and today's change.
Galapagos N.V. Cash Flow Conversion Ratio Explained
Galapagos N.V. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Galapagos N.V. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galapagos N.V. ranked by their cash flow conversion efficiency. Also see GLPG company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Tofflon Science Tech
SHE:300171
|
0.006x |
|
AG Anadolu Group Holding
IS:AGHOL
|
0.114x |
|
Grand City Properties SA
XETRA:GYC
|
0.006x |
|
eClerx Services Limited
NSE:ECLERX
|
0.131x |
|
Elvalhalcor Hellenic Copper and Aluminium Industry S.A
AT:ELHA
|
0.104x |
|
China Railway Construction Corporation Limited
F:4FF
|
0.045x |
|
Tongyu Heavy Industry
SHE:300185
|
0.004x |
|
Sharplink Gaming Ltd
NASDAQ:SBET
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Galapagos N.V. (2004–2025)
The table below shows the annual cash flow conversion efficiency of Galapagos N.V. from 2004 to 2025. Review Galapagos N.V. free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €3.24 Billion ≈ $3.78 Billion |
€-197.01 Million ≈ $-230.32 Million |
-0.061x | +44.89% |
| 2024-12-31 | €2.90 Billion ≈ $3.39 Billion |
€-320.03 Million ≈ $-374.14 Million |
-0.110x | +23.93% |
| 2023-12-31 | €2.80 Billion ≈ $3.27 Billion |
€-405.97 Million ≈ $-474.62 Million |
-0.145x | +26.71% |
| 2022-12-31 | €2.53 Billion ≈ $2.95 Billion |
€-500.54 Million ≈ $-585.19 Million |
-0.198x | -3.96% |
| 2021-12-31 | €2.64 Billion ≈ $3.09 Billion |
€-503.83 Million ≈ $-589.03 Million |
-0.191x | -19.10% |
| 2020-12-31 | €2.67 Billion ≈ $3.12 Billion |
€-427.34 Million ≈ $-499.60 Million |
-0.160x | -114.34% |
| 2019-12-31 | €2.88 Billion ≈ $3.36 Billion |
€3.21 Billion ≈ $3.75 Billion |
1.116x | +1050.99% |
| 2018-12-31 | €1.21 Billion ≈ $1.42 Billion |
€-142.47 Million ≈ $-166.56 Million |
-0.117x | +19.24% |
| 2017-12-31 | €1.01 Billion ≈ $1.18 Billion |
€-147.03 Million ≈ $-171.89 Million |
-0.145x | -146.04% |
| 2016-12-31 | €758.70 Million ≈ $887.00 Million |
€239.40 Million ≈ $279.89 Million |
0.316x | +200.51% |
| 2015-12-31 | €365.00 Million ≈ $426.72 Million |
€-114.59 Million ≈ $-133.97 Million |
-0.314x | +14.35% |
| 2014-12-31 | €206.13 Million ≈ $240.99 Million |
€-75.56 Million ≈ $-88.33 Million |
-0.367x | -11835.82% |
| 2013-12-31 | €167.14 Million ≈ $195.40 Million |
€522.00K ≈ $610.27K |
0.003x | -99.42% |
| 2012-12-31 | €118.45 Million ≈ $138.48 Million |
€64.10 Million ≈ $74.94 Million |
0.541x | +634.28% |
| 2011-12-31 | €118.38 Million ≈ $138.39 Million |
€-11.99 Million ≈ $-14.02 Million |
-0.101x | +19.01% |
| 2010-12-31 | €148.51 Million ≈ $173.62 Million |
€-18.57 Million ≈ $-21.71 Million |
-0.125x | -316.03% |
| 2009-12-31 | €108.88 Million ≈ $127.29 Million |
€6.30 Million ≈ $7.37 Million |
0.058x | +159.47% |
| 2008-12-31 | €84.32 Million ≈ $98.58 Million |
€-8.21 Million ≈ $-9.60 Million |
-0.097x | -2687.95% |
| 2007-12-31 | €98.63 Million ≈ $115.30 Million |
€371.00K ≈ $433.74K |
0.004x | +104.43% |
| 2006-12-31 | €109.54 Million ≈ $128.07 Million |
€-9.31 Million ≈ $-10.88 Million |
-0.085x | -33.68% |
| 2005-12-31 | €61.14 Million ≈ $71.47 Million |
€-3.89 Million ≈ $-4.54 Million |
-0.064x | +75.68% |
| 2004-12-31 | €10.37 Million ≈ $12.12 Million |
€-2.71 Million ≈ $-3.17 Million |
-0.261x | -- |
About Galapagos N.V.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory no… Read more